SCHEMBL5747018

SCHEMBL5747018

O=[N+]([O-])c1cc[c]c(Cl)c1Cl

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 5/20 0.50
TSHR P16473 4/20 0.39
MAPK1 P28482 1/20 0.39
GPR35 Q9HC97 2/20 0.38
HTR2A P28223 2/20 0.38
HTR2C P28335 2/20 0.38
HTR2B P41595 2/20 0.38
VCAM1 P19320 3/20 0.37
ALDH1A1 P00352 3/20 0.37
CYP3A4 P08684 1/20 0.37
HPGD P15428 1/20 0.37
ALOX15 P16050 1/20 0.37
HIF1A Q16665 1/20 0.37
TXNRD1 Q16881 1/20 0.37
TXNRD3 Q86VQ6 1/20 0.37
TXNRD2 Q9NNW7 1/20 0.37
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
POLB P06746 1/20 0.35
MAPT P10636 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11049111 0.82 TSHR (0.41) TDP1TSHRMAPK1GPR35VCAM1
SCHEMBL13836217 0.80 TDP1 (0.50) TDP1TSHRMAPK1GPR35ALDH1A1
SCHEMBL28123479 0.80 TDP1 (0.47) TDP1TSHRMAPK1GPR35HTR2A
SCHEMBL27670471 0.80 TDP1 (0.41) TDP1TSHRMAPK1VCAM1ALDH1A1
SCHEMBL28002943 0.76 TDP1 (0.43) TDP1TSHRMAPK1GPR35HTR2A
SCHEMBL16974731 0.76 TDP1 (0.41) TDP1TSHRMAPK1ALDH1A1HPGD
SCHEMBL28003241 0.76 ALDH1A1 (0.37) TDP1TSHRMAPK1GPR35VCAM1
SCHEMBL1179475 0.75 TDP1 (0.45) TDP1TSHRMAPK1GPR35ALDH1A1
SCHEMBL9342102 0.74 ALDH1A1 (0.44) TDP1TSHRMAPK1VCAM1ALDH1A1
SCHEMBL8012114 0.74 TDP1 (0.39) TDP1TSHRMAPK1VCAM1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0296673-B1 Thiazole derivatives SHELL INT RESEARCH (NL) 1994-03-09 EP claimed
US-4877802-A FUNGICIDES SHELL INTERNATIONALE RESEARCH MAATSCHAPPIJ B.V. (NL) 1989-10-31 US claimed
EP-0296673-A1 Thiazole derivatives SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) 1988-12-28 EP claimed
US-20150237857-A1 ANTIBACTERIAL INHIBITORS MCMASTER UNIVERSITY (CA) 2015-08-27 US disclosed
EP-2882430-A1 ANTIBACTERIAL INHIBITORS McMaster University (CA) 2015-06-17 EP disclosed
WO-2014022923-A1 ANTIBACTERIAL INHIBITORS MCMASTER UNIVERSITY (CA) 2014-02-13 WO disclosed
EP-1345942-B9 PYRAZINOQUINOXALINE DERIVATIVES AS SEROTONIN AGONISTS AND ANTAGONISTS BRISTOL MYERS SQUIBB PHARMA CO (US) 2006-11-15 EP disclosed
EP-1345942-B1 PYRAZINOQUINOXALINE DERIVATIVES AS SEROTONIN AGONISTS AND ANTAGONISTS BRISTOL MYERS SQUIBB PHARMA CO (US) 2006-03-01 EP disclosed
US-6638934-B2 2,3,4,4a,5,6-hexahydro-1H-pyrazino(1,2-a)quinoxaline derivatives; treating depression, schizophrenia; (5-hydroxytryptamine=5HT) 5HT2a antagonist or a 5HT2c agonist BRISTOL-MYERS SQUIBB PHARMA COMPANY 2003-10-28 US disclosed
EP-1345942-A2 PYRAZINOQUINOXALINE DERIVATIVES AS SEROTONIN AGONISTS AND ANTAGONISTS Bristol-Myers Squibb Pharma Company (US) 2003-09-24 EP disclosed
US-20020177596-A1 Substituted pyrazinoquinoxaline derivatives as serotonin receptor agonist and antagonists ligands BRISTOL-MYERS SQUIBB PHARMA COMPANY 2002-11-28 US disclosed
WO-2002059127-A2 PYRAZINOQUINOXALINE DERIVATIVES AS SEROTONIN AGONISTS AND ANTAGONISTS BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2002-08-01 WO disclosed
EP-0296673-B1 Thiazole derivatives SHELL INT RESEARCH (NL) 1994-03-09 EP disclosed
US-4877802-A FUNGICIDES SHELL INTERNATIONALE RESEARCH MAATSCHAPPIJ B.V. (NL) 1989-10-31 US disclosed
EP-0296673-A1 Thiazole derivatives SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) 1988-12-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020177596-A1 Substituted pyrazinoquinoxaline derivatives as serotonin receptor agonist and antagonists ligands HTR1A, HTR5A, HTR1D TDP1 4464/4885TSHR 254/4885MAPK1 1094/4885
US-20150237857-A1 ANTIBACTERIAL INHIBITORS MRPL21, Q6ZSR9, SPOUT1 TDP1 3742/4885TSHR 4204/4885MAPK1 711/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.